Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B

By Ting Chang, Y. Liaw, Shun‐Sheng Wu, E. Schiff, K. Han, Ching‐lung Lai, R. Safadi, Samuel S. Lee, W. Halota, Z. Goodman and 6 more. Hepatology, 2010

955 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Surgery

View Paper: https://www.semanticscholar.org/paper/aa3b4e0c5ac27db7824d59ead2867a16a1fc0ef7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. M. Pinzani
2. S. Friedman
3. Christian Trautwein
4. Ralf Weiskirchen
5. Y. Saiman
6. J. Puche
7. A. Gressner
8. D. Brenner

In Hepatology

1. M. Pinzani
2. S. Friedman
3. Christian Trautwein
4. Ralf Weiskirchen
5. Y. Saiman
6. J. Puche
7. A. Gressner
8. J. Bonner

In Surgery

1. S. Friedman

Citations in the corpus

• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. (2012, background): “Regression of fibrosis and even reversal of cirrhosis have been reported in patients with prolonged suppression of viral replication [150].”
• Hepatic fibrosis: Concept to treatment. (2015, methodology): “This focus on NASH reflects both the astonishing improvement in the specific therapies for viral hepatitis, combined with the growing appreciation of the magnitude of the obesity and fatty liver disease epidemics, which affects up to tenfold more individuals than HCV in the US and Europe.”